Driehaus Capital Management LLC Castle Biosciences Inc Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $14 Million - $24.2 Million	-358,200 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$60.13 - $77.6 $1.28 Million - $1.65 Million	-21,293 Reduced 5.61%	358,200 $23.8 Million
Q2 2021 Aug 16, 2021	BUY	$50.07 - $76.78 $29,090 - $44,609	581 Added 0.15%	379,493 $27.8 Million
Q1 2021 May 17, 2021	SELL	$58.92 - $97.33 $3.05 Million - $5.05 Million	-51,844 Reduced 12.04%	378,912 $25.9 Million
Q4 2020 Feb 16, 2021	SELL	$43.6 - $73.05 $555,028 - $929,926	-12,730 Reduced 2.87%	430,756 $28.9 Million
Q3 2020 Nov 16, 2020	SELL	$38.47 - $52.03 $204,429 - $276,487	-5,314 Reduced 1.18%	443,486 $22.8 Million
Q2 2020 Aug 14, 2020	BUY	$27.28 - $43.01 $1.15 Million - $1.81 Million	41,983 Added 10.32%	448,800 $16.9 Million
Q1 2020 May 15, 2020	BUY	$23.08 - $35.53 $950,549 - $1.46 Million	41,185 Added 11.26%	406,817 $12.1 Million
Q4 2019 Feb 12, 2020	BUY	$15.74 - $35.04 $1.34 Million - $2.99 Million	85,231 Added 30.4%	365,632 $12.6 Million
Q3 2019 Nov 14, 2019	BUY	$18.09 - $27.92 $5.07 Million - $7.83 Million	280,401 New	280,401 $5.07 Million

202

24.5M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $712M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.